The Monash IVF Group Ltd (ASX: MVF) share price is tumbling in early morning trade on Thursday. At the time of writing, the shares are down 6.88% The latest price movement follows the company’s half-year results, which it posted ahead of the ASX open this morning.
This morning’s decrease means the stock is now 14.4% lower for the year to date and down 45.13% over the year.
What did Monash IVF report?
Here’s what the specialist assisted reproductive services provider posted for the six months ending 31st December 2025:
- Revenue down 1.8% to $137.9 million
- Underlying EBITDA down 15.3% to $30.2 million
- Underlying EBIT down 27.5% to $17.5 million
- Underlying NPAT down 34% to $10.4 million
- Fully-franked dividend of 1.2 cents per share
What happened in the first half of FY26?
Monash IVF Group has announced a group revenue of $137.9 million for the first half of FY26, down 1.8% from the prior corresponding period (pcp). The company said the decrease was largely driven by industry softness and domestic IVF market-share loss, and occurred despite consistent IVF pricing across key states.
Revenue was also partly offset by price growth and an increase in international revenue.
The company’s underlying EBITDA dropped 15.3% to $30.2 million, and its underlying EBIT declined 27.5% to $17.5 million. This was largely driven by a 2.5% decline in market share. Domestic and international EBITDA dragged on the results.
Monash IVF’s underlying net profit of $10.4 million was down 34% for the first half of the financial year, aligning with previous guidance.
The board has declared a fully-franked interim dividend of 1.2 cents per share for investors.Â
What else did Monash IVF report?
The company confirmed that its recruitment process for a new Chief Financial Officer is still underway and progressing well. The board expects to provide a further market update once an appointment has been finalised. Malik Jainudeen will continue in his role as Chief Financial Officer during this transition period to ensure continuity and stability.
What’s ahead for the company this year?
Looking ahead, Monash IVF anticipates underlying net profit of approximately $20 million for FY26.
Capital expenditure for the full year is anticipated to be $16 to $17 million, noting the completion of the new clinical infrastructure program during Q4 FY26.
Net debt at 30 June 2026 is expected to be approximately $95 million, and a net leverage ratio of 2.0x, which is well below banking covenant requirements of below 3.5x.
The post Monash IVF shares tumble 7% off the back of its half-year results appeared first on The Motley Fool Australia.
Should you invest $1,000 in Monash IVF Group right now?
Before you buy Monash IVF Group shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Monash IVF Group wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- 9,200 points: ASX 200 hits fresh new record high
- Objective Corporation 1H FY26: profit climbs, dividend declared
- Cleanaway Waste Management reports half-year profit and upgrades FY26 guidance
- IDP Education shares surge 12% on upgraded FY26 guidance
- Sigma shares jump 7% on results and Chemist Warehouse expansion
Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.